Denosumab 120mg

Denosumab 120mg

Product Overview

Generic NameDenosumab 120mg
Brand Name(s)Prolia®, Xgeva®; biosimilars:
CategoryAntibodies, monoclonal
FormSubcutaneous injection solution (vial)
Strength120 mg
Therapeutic ClassRANKL inhibitor; bone density conservation agent
ATC CodeM05BX04

Manufacturing & Regulatory

ManufacturerIntas Pharmaceuticals
GMP ComplianceWHO/cGMP-compliant
DMF/CEPType II
COFEPRIS010.000.6013.00
Free Sale CertificateAvailable from supplier on request

Logistics & Export

MOQ5 units
Shelf Life24 Months
StorageRefrigerated 2–8 °C; bring to room temp before use
IncotermsEXW/CIF negotiable
Lead Time7 - 10 Business Days

Documentation Available Upon Request

Certificate of Analysis (PDF)Supplied per batch upon request
SDS-Safety Data Sheet (PDF)available from manufacturer/distributor
CTD Summary (PDF)proprietary; may be available upon commercial commitment/documentation fee

Special Notes

Denosumab is a human monoclonal antibody indicated for the treatment of osteoporosis in postmenopausal women and men at high risk of fracture, bone loss due to hormone ablation in cancer, and for prevention of skeletal-related events in patients with bone metastases from solid tumors. It works by inhibiting RANKL, thereby reducing bone resorption.